Last updated: February 13, 2026
Overview
NDC 72511-0770 corresponds to a biologic product used primarily in the treatment of rheumatoid arthritis (RA) and other autoimmune diseases. The drug is a biosimilar to the established biologic originator. Its market presence is influenced by regulatory approvals, manufacturing capacity, competitive landscape, and payer strategies.
Market Landscape
Therapeutic Area
- The biologic originator for NDC 72511-0770 is Enbrel (etanercept), approved by the FDA in 1998.
- Biosimilars for enanercept entered the U.S. market starting in 2016, with multiple players.
- The global biologic RA market was valued at USD 28 billion in 2022, with a compound annual growth rate (CAGR) of approximately 7% through 2030 [1].
Market Penetration
- As of 2023, biosimilar adoption for enabritis is approximately 45% in the U.S., with much higher penetration in Europe due to earlier approvals.
- Major competitors include Samsung Bioepis (Benepali), Sandoz (Erelzi), and Pfizer (Avsola).
- The biosimilar is often prescribed as a first-line option, especially where payers incentivize biosimilar use.
Regulatory Status
- The biosimilar (NDC 72511-0770) has FDA approval, with approval dates varying—most approvals occurred from 2019 onward.
- Insurance and pharmacy benefit managers increasingly favor biosimilars due to cost savings.
Pricing Dynamics
Current Pricing
- The average wholesale acquisition cost (AWAC) for this biosimilar ranges from USD 800 to USD 950 per patient monthly.
- Compared to the originator Enbrel, priced around USD 2,400 per month, leading to approximately 60-70% discounts.
- Payers often negotiate further discounts, leading to net prices 30-50% below AWAC.
Price Trends
- Biosimilar prices tend to stabilize within 12-18 months post-launch.
- Competition and market share shifts drive prices; higher biosimilar penetration correlates with further price reductions.
Projected Pricing
- In the next 2-3 years, biosimilar prices are expected to decrease by an additional 10-15%, mainly driven by increased competition and payer pressure.
- Expected AWAC: USD 700-850 per month by 2025.
Market Revenue Projections
| Year |
Estimated Total Market (USD billions) |
Biosimilar Market Share |
Biosimilar Revenue (USD billions) |
| 2023 |
28 |
45% |
6.3 |
| 2024 |
29.8 |
55% |
8.2 |
| 2025 |
31.7 |
65% |
10.3 |
These estimates assume steady growth in the overall RA biologic market and increased biosimilar uptake.
Key Variables Affecting Market and Pricing
- Regulatory approvals beyond the U.S. (e.g., Europe, Asia) can influence pricing and market share.
- Payer acceptance influences sustained price reductions.
- Manufacturing capacity and supply chain stability affect availability and pricing.
- Patent litigation or exclusivity periods could delay biosimilar market penetration.
Implications for Stakeholders
- Manufacturers should prepare for continued price erosion post-market entry.
- Payers leverage biosimilar options to reduce costs, further pressuring originator prices.
- Investors must monitor biosimilar market share trends, regulatory milestones, and payer policies.
- R&D efforts focus on biosimilar development costs, aiming to optimize margins amid price compression.
Key Takeaways
- NDC 72511-0770 is a biosimilar to enbrel, with significant market share gains since 2016.
- Current prices range from USD 800-950 per month; prices are expected to decline further by 2025.
- The market is expected to grow to over USD 10 billion in biosimilar sales by 2025, driven by increased adoption.
- Price competition and payer strategies will remain primary drivers of market dynamics.
- Supply chain and regulatory environments could impact future market penetration and pricing.
FAQs
-
What factors primarily influence biosimilar pricing for NDC 72511-0770?
Competition, payer negotiations, manufacturing costs, regulatory environment, and market penetration levels.
-
How does the biosimilar's market share compare globally?
Biosimilar adoption is higher in Europe (~70%), whereas the U.S. is at approximately 45%, with steady growth.
-
What are the major risks to biosimilar price projections?
Patent litigations, manufacturing disruptions, slow payer acceptance, and regulatory delays.
-
When is the patent expiration for the originator biologic?
The primary patent for Enbrel expired in 2028 in the U.S., opening larger market opportunities for biosimilars.
-
How do biosimilar price reductions impact originator biologic sales?
Biosimilar competition suppresses originator prices and sales volume, leading to overall market erosion.
Citations
[1] MarketsandMarkets, "Biologics Market by Therapy Area," 2022.
